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Abstract
Protein kinase Cy (PKCy) is one of the functionally distinct isoforms in PKC family. p300 is a histone acetyltransferase/transcription
coactivator. They share certain properties, such as ubiquitous expression, growth and tumor suppression, and ability to enhance differentiation
and apoptosis. In this study, we found that PKCy but not classical PKC, specifically phosphorylates p300 at serine 89 in vitro and in vivo. This
phosphorylation causes inhibition of p300 intrinsic HAT activity. Subsequently, the targeted acetylation of nucleosomal histones is markedly
reduced, which causes repression of p300 transcription coactivator function. These findings identify a new signal transduction pathway by
which PKCy may inhibit cell growth and promote cellular differentiation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
CBP/p300 is one of the most studied transcriptional
coactivators and histone acetyltransferases (HAT). The bind-
ing of E1A to CBP/p300 inhibits the HAT and transcrip-
tional activities of CBP/p300 [1–4]. Although the precise
mechanism of this inhibition remains unclear, it has been
proposed that E1A interacts directly with the CBP/p300
HAT domains as well as disrupts the interactions of asso-
ciated HATs, such as PCAF [5]. The basic helix–loop–
helix protein Twist, implicated in inhibiting differentiation
of multiple cell lineages, can directly target the HAT
domains of CBP and p300, and inhibit their enzymatic
activity [3].
Phosphorylation is known to be an important mode of
transcription factor regulation [6]. Phosphorylated p300 has
been found in both quiescent and proliferating cells, and the
level of p300 phosphorylation changes along the cell cycle
progression [7]. Several reports have suggested that CBP/
p300 may be phosphorylated by various kinases that are
important in either cell cycle regulation or in different signal
transduction pathways. Furthermore, these phosphorylation
events have been speculated to affect various CBP/p300
activities [8–12]. Recently, the first in vivo phosphorylation
site (serine 89) in p300 has been identified [13]. This
previous report also showed that PKCa had the strongest
activity in HeLa to phosphorylate serine 89 in a p300
fragment, and this serine 89 phosphorylation appeared to
repress p300-participated gene expression. However, in
above phosphorylation studies, the precise kinase respon-
sible for the specific phosphorylation of p300 in vivo and
the physiological significance of the phosphorylation
remains unclear.
PKC is a family of serine/threonine kinases that contain
the similar regulatory C1 domain structure that responds to
the lipid second messenger, diacylglycerol, for activation
[14,15]. Different PKC isoforms are unique to each other in
their function and so play distinct roles in signal trans-
duction [16,17]. Therefore, it is essential to identify the
specific PKC isoform responsible for the phosphorylation in
order to understand the physiological significance of the
event. We found in the current study that PKCy, but not
PKCa as reported previously, is responsible for the phos-
phorylation of p300 at serine 89. Further, PKCy-mediated
phosphorylation inhibits p300 intrinsic HAT activity. The
same physiological roles of both p300 and PKCy support
our conclusion that they collaborate in the same signal
transduction pathway.
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2. Materials and methods
2.1. Protein purification
The flag-tagged p300 proteins (rp300), including wild
type and the point mutant at serine 89 to alanine (S89A),
were expressed in Sf9 cells using the Baculoviral expres-
sion system (BRL Biotechnology) and purified through
P11 (Whatman) and anti-flag immuno-affinity (M2-Agar-
ose, Kodak) chromatography. The 6His-tagged Gal-
CREB fusion protein phosphorylated at serine 133 (P-
Gal-CREB) was co expressed in bacteria with PKA
catalytic subunit using pET expression system (Novogen).
The fusion proteins were then purified by P11 and Ni2-
NTA Agarose (Qiagen) chromatography following ammo-
nium sulfate precipitation (25–40%), and analyzed by
Western blotting with the anti-CREB phospho-serine 133
antibody.
2.2. In vitro phosphorylation
The purified rp300 protein (100 ng) was phosphorylated
by either purified recombinant PKCa (Calbiochem),
PKChII [13], PKCy (Calbiochem), or PKCu immunopreci-
pitated from HeLa cells [18]. The activity of the PKC
kinases was verified by phosphorylation using myelin basic
protein (MBP, Biomol, 1 Ag) as substrate. The phosphor-
ylation reaction was carried out at 30 jC for 20 min in
kinase buffer (20 mM Hepes pH 7.4, 10 mM magnesium
acetate, 1 mM DTT, and 20 AM ATP) supplemented with
0.5 mM CaCl2, 100 ng/ml PMA, 100 Ag/ml phosphatidyl-
serine. After phosphorylation, rp300 and MBP were ana-
lyzed by 6% and 12% SDS-PAGE, respectively. For further
HAT and transcription assays, phosphorylated rp300 was
recovered by using M2-Agarose to separate from the
kinases.
2.3. HAT assay
The HAT activity of the purified rp300 proteins (200 ng,
or as indicated) was assayed with either free core histones
(0.5 Ag) or the nucleosomes-assembled plasmid pT3G5 (5
Ag) as substrates, and analyzed by the PAGE method
[19,20]. The chromatin DNA was incubated with the serine
133-phosphorylated Gal4-CREB fusion protein (P-Gal-
CREB) and rp300 before the HAT assays. Transfected
flag-tagged p300 and endogenous p300 were prepared by
immunoprecipitation from cell lysates with anti-flag or anti-
p300 antibody, and assayed for HAT activity with free core
histones (0.5 Ag) as substrates using the filter-binding
method [20].
2.4. Nucleosomes assembly
Nucleosomes were assembled on the plasmid pT3G5 by
the octomer transfer method using the short chromatin of
HeLa cells as described previously [21–24]. The plasmid
pT3G5 was derived from a transcriptional template
(pG5HMC2AT) [25] containing a mammalian promoter
with upstream Gal4-binding sites, multiple Sp1 sites and a
downstream G-less cassette. pT3G5 also contains 10 copies
of the nucleosome positioning sequence of 5S rDNA in
order to help nucleosome assembly. The nucleosome-
assembled DNA was purified by sucrose gradient centrifu-
gation. The quality of the chromatin was analyzed by
micrococcal nuclease digestion.
2.5. In vitro transcription assay
Assays were carried out as described previously
[21,24,26] except using HeLa nuclear extracts instead of
the purified basal transcription factors. Transcription reac-
tion (50 Al) contained 20 mM Tris–HCl (pH 7.9), 100 mM
KCl, 0.2 mM EDTA, 3 mM MgCl2, 150 U RNase T1, 0.5
mM ATP, 0.5 mM CTP, 25 AM UTP, 100 AM 3V-O-methyl
GTP (Pharmacia), 1 Al [a-32P] UTP (NEN, 3000 Ci/mmol,
10 mCi/ml), acetyl CoA (1 AM), TSA (5 AM), HeLa
nuclear extracts (50 Ag), either P-Gal-CREB (100 ng) or
rp300 (400 ng), and the DNA template (pT3G5 plasmid),
either naked (100 ng) or reconstituted chromatin (1 Ag). A
core promoter template (pMLD53, 40 ng) was also
included in the reaction as a control [27]. After incubation
at 30 jC for 60 min, the reaction was stopped by adding
200 Al stop solution (20 mM Tris–Cl, pH 8.0, 1 mM
EDTA, 100 mM NaCl, and 1% SDS) and 1 Ag tRNA as
carrier. After extraction with phenol/chloroform (1:1), RNA
was precipitated with ethanol, and analyzed on a 5%
polyacrylamide gel containing 8 M urea. After electro-
phoresis, the gel was soaked in dH2O, dried, and subjected
to autoradiography.
2.6. Transfection and CAT assay
HeLa cells at 50% confluence growing in DMEM/5%
fatal calf serum in 10-cm plates were transfected with
Lipofectamine (16 Al, BRL) according to the manufacturer’s
instruction. One or two days after transfection, the cells
were lysed in 200-Al buffer (250 mM Tris–HCl, pH 7.4, 1
mM DTT, and 1 mM PMSF) followed by CAT assay using
the organic phase extraction procedure [28]. CAT activity
was normalized against cotransfected h-galactosidase activ-
ity [29].
The transfected cells, after recovery, may be treated
either with PMA (100 nM) for 1 h, or with Calphostin C
(100 nM) until harvest. HeLa cells expressing either
constitutively active (CA, aa 326–672, CAT) or domi-
nantly negative (DN, K368R) mutant of PKCa, or CA (aa
334–674) or DN (K376R) mutant of PKCy, were prepared
by stable transfection as described previously [18]. The
stable cell lines were selected in the medium containing
800 Ag/ml G418 (BRL), and maintained with 200 Ag/ml
G418.
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3. Results
3.1. PKCd phosphorylates p300 at serine 89 solely
In previous report [13], two classical PKCs (cPKC),
PKCa and PKChII, and a novel PKC, PKCy, phosphorylated
serine 89 in a small fragment of p300 (rp300n, aa 74–163). In
current study, the recombinant full-length p300 proteins
(rp300), wild type and the point mutant at serine 89 to alanine
(rp300 S89A), were expressed and purified from Sf9 cells
(Fig. 1A). In in vitro kinase assays and detection with the
phospho-serine 89-specific antiserum, both PKCa and PKCy
phosphorylated serine 89 of rp300 (Fig. 1B). However, PKCy
phosphorylated only wild type rp300 but not the S89A
mutant (Fig. 1C), suggesting that PKCy phosphorylated
serine 89 in p300 solely. In contrast, PKCa phosphorylated
both wild type and S89A mutant of rp300 (Fig. 1C), indicat-
ing that PKCa also phosphorylated p300 residue(s) other
than serine 89. As same as PKCa, PKChII also phosphory-
lated rp300 at serine 89 and other residue(s) (data not shown).
3.2. PKCd inhibits p300 intrinsic HAT activity
To examine whether PKC-mediated phosphorylation
affects p300 function directly, we carried out HAT assays
using free core histones after phosphorylation of the rp300
proteins with either PKCa or PKCy and further separation of
the phosphorylated p300 proteins from the kinase. The HAT
activity of wild type rp300 was markedly reduced by the
PKCy-mediated phosphorylation (Fig. 2A, left). PKCy did
not affect the HATactivity of rp300 S89A, indicating that the
repression of p300 HAT activity is specific to the phosphor-
ylation at serine 89. Interestingly, after phosphorylation with
PKCa, the HAT activity of the S89A mutant was increased
(Fig. 2A, right), suggesting that PKCa-mediated phosphor-
ylation at the other putative residue(s) favors p300 HAT
function. On the other hand, wild type p300, after phosphor-
ylation at both serine 89 and the other putative residues by
PKCa, was not affected in its HAT activity. This result
Fig. 1. PKCy phosphorylates full-length p300 at serine 89 solely. (A) Co-
omassie staining of recombinant p300 (rp300) proteins, wild type (WT) and
the serine 89 point mutant (S89A). The rp300 proteins were expressed in and
purified from Sf9 cells. (B) Western blot analysis of the rp300 proteins with
anti-phospho-serine 89 antiserum after phosphorylation by either PKCy or
PKCa. (C) Autoradiograph demonstrating phosphorylation of rp300 (left)
and MBP (1 Ag; right) by different isoforms of PKC.
Fig. 2. Inhibition of p300 HAT activity via phosphorylation at serine 89 by
PKCy. (A) The rp300 proteins were expressed in and purified from Sf9 cells.
The rp300 preparation has been optimized to have a similar background in
HAT activity between the wild type and the S89A mutant. The rp300
proteins treated with kinases were purified further to separate from the
kinases. Fluorographs are shown at the bottom, indicating acetylation of free
core histones by rp300 with and without phosphorylation by either PKCa or
PKCy. The HAT assay is analyzed quantitatively with a phosphoimager (top
graph). Error bars represent the standard deviation (n= 3). (B) HAT assays
for rp300, either wild type (WT) or the serine 89 mutant (S89A), with or
without phosphorylation by PKCy in the presence or absence of Gal-CREB
fusion protein phosphorylated at serine 133 (P-Gal-CREB). The pT3G5
chromatin was used as substrate in the assays.
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indicates that the inhibitory effect of the serine 89 phosphor-
ylation and the stimulating effect of the non-serine 89
phosphorylation were neutralized by each other.
When we used nucleosomes-assembled plasmid chroma-
tin (pT3G5) as substrates in HAT assays, the results were
identical to those using free histones (Fig. 2B). In addition,
efficiency of rp300 to acetylate nucleosomes depended on
activator Gal-CREB phosphorylated at serine 133 (P-Gal-
CREB) (Fig. 2B), which bound to the nucleosomal DNA
through the Gal4 sites and recruited rp300 onto the chromatin
[4]. This p300 targeting for acetylation is similar to the pre-
vious observation that GCN5 HAT protein and transcription
coactivator targeted acetylation of nucleosomal histone [24].
Importantly, serine 89 phosphorylation by PKCy reduced the
ability of p300 to target acetylation of nucleosomes.
3.3. Overall PKC does not inhibit p300 HAT activity in vivo
We further carried out functional assays in vivo. The
expression vectors for the flag-tagged p300, both wild type
and the S89A mutant, were transfected into HeLa cells,
respectively. After transfection, cells were either untreated
or treated with PKC activator phorbol 12-myristate 13-
acetate (PMA) or with PKC-specific inhibitor Calphostin
C. The flag-p300 proteins were recovered by immunopreci-
pitation with anti-flag antibodies. Both wild type and S89A
rp300 proteins expressed in similar amounts in all treated and
untreated cells (Fig. 3A, bottom), suggesting that PMA and
Calphostin C had no effect on expression of rp300. PKC
activator PMA increased while the inhibitor Calphostin C
decreased the level of p300 phosphorylation at serine 89
(Fig. 3A, middle), confirming that PKC mediates the serine
89 phosphorylation in vivo. The reduction of the serine 89
phosphorylation of p300 was also observed in the cells
treated with either Go6976 (50 nM) or Rottlerin (30AM)
(data not shown), implying that both cPKCs and PKCy
mediate in vivo phosphorylation of serine 89.
In normal HeLa cells, the p300 S89A point mutant was
more active than the wild type p300 in acetylation of histones
(Fig. 3A, top left), suggesting that phosphorylation at serine
89 inhibited p300 HAT function in vivo, just as it did in vitro.
The HAT activity of the p300 mutant S89A was increased
significantly in PMA-treated cells (Fig. 3A, top middle). In
this case, the mutant did not have any serine 89 phosphor-
ylation but should have an increased phosphorylation level at
the putative non-serine 89 residues because PMA activates
PKCa, too. Similar to the in vitro situation (Fig. 2A), non-
Fig. 3. PKCymediates phosphorylation of p300 at serine 89 and subsequent
inhibition of HAT activity in vivo. (A) HeLa cells were transfected tran-
siently with the flag-tagged p300 constructs, either wild type (WT), or the
serine 89 point mutant (S89A), or the empty vector (– ). After transfection,
cells were either untreated (Normal) or treated with PMA or Calphostin C
(Cal C). The flag-p300 proteins were recovered by immunoprecipitation
with antibody against the flag tag, analyzed by HAT assays (top), and by
Western blotting (bottom) with antiserum against phospho-serine 89 (P-S89-
flag-p300) and antibody to p300 (flag-p300). (B,C) HeLa cells were
transfected stably with PKCa or PKCy constitutively active (CA) or do-
minantly negative (DN) mutant. The mutant proteins were immunopreci-
pitated with antibody against the HA tag, analyzed by Western blotting with
antibody against either PKCa or PKCy (bottom), and assayed for kinase
activity with MBP as substrate (top) (B). The endogenous p300 proteins
were immunoprecipitated with the antibody to p300 from different cells, and
analyzed by HAT assays (top) and by Western blotting (bottom) with the
antiserum against phospho-serine 89 (P-p300) and the antibody to p300
(p300) (C). The immunoprecipitation with the antibody to the flag tag (flag)
was used as a control. HAT activity was assayed using free core histones as
substrates and normalized against total proteins. Error bars represent the
standard deviation (n= 3–5).
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serine 89 phosphorylation had stimulating effect on the p300
HAT activity. In the cells with different treatment, phosphor-
ylation level at serine 89 of the wild type rp300 was
increased by PMA and reduced by Calphostin C while the
HATactivity was not affected significantly by the changes of
the serine 89-phosphorylation level (Fig. 3A). This may be
resulted at least in part by the simultaneous change of PKCa-
mediated phosphorylation level at the other putative resi-
dues, which neutralizes the inhibitory effect of the serine 89
phosphorylation as we observed in vitro.
3.4. PKCd mediates repression of p300 HAT in vivo
To investigate whether PKCy mediates repression of the
p300 HAT activity in vivo, we used HeLa cells stably
expressing either CA or DN mutant of PKCa or PKCy
[18]. The specificity of the enzymatic reaction for these CA
and DN mutants in the transfected cells is shown in Fig. 3B,
which is consistent with the previous observation [18]. The
levels of p300 in all PKCa and PKCy CA- and DN-
expressing cells were similar, and no significant difference
from that in normal HeLa cells (Fig. 3C, bottom), suggest-
ing that these PKCa and PKCy mutants do not affect the
expression of p300. As expected, both PKCa and PKCy CA
mutants increased and both DN mutants reduced the phos-
phorylation level at serine 89 (Fig. 3C, bottom). In the cell
cotransfected with PKCy CA mutant that over-expressed
PKCy activity, the p300 HAT activity was inhibited while
the HAT activity was enhanced in the cell overexpressing
PKCy DN mutant (Fig. 3C, top). In contrast, in the cell
cotransfected with either PKCa CA or DN mutant, the p300
HAT activity was not affected (Fig. 3C, top). These results
indicate that PKCy, rather than PKCa, is responsible
directly for the inhibition of the p300 HAT activity in vivo.
The difference in the p300 HAT activity between the cells
expressing either mutant type of PKCa and PKCy, respec-
tively, did not reflect their similar phosphorylation levels at
serine 89 (Fig. 3C). Similar to the situations in vitro and in
the PMA or Calphostin C-treated cells, this result can be
explained by the facts that PKCy phosphorylates p300 only
at serine 89, resulting in inhibition of the p300 HAT activity
while PKCa phosphorylates both serine 89 and non-serine
89 residues, which neutralize the effect on p300 HAT. The
expression of PKCa CA mutant increased while the expres-
sion of PKCa DN mutant decreased phosphorylation of
both serine 89 and the other putative residues, therefore each
resulting neutral effect on the p300 HAT activity. Because
the rp300 proteins used in the HAT assays were prepared
from cells by immunoprecipitation, the measured HAT
activity may be affected by change in the association of
p300 with other HAT proteins. The measured HAT activity
of p300 might also be affected by the PKC mutants in serine
89-phosphorylation-independent ways. In summary, our
data suggest that PKCy plays a major role in the serine
89-phosphorylation-dependent repression of p300 HAT
activity in vivo.
3.5. PKCd inhibits transcription on chromatin
Further in vitro transcription assays using the transcrip-
tion template pT3G5, either naked DNA or reconstituted
chromatin, were carried out in HeLa nuclear extracts supple-
mented with either P-Gal-CREB or rp300 proteins. Tran-
Fig. 4. PKCy inhibits p300 transcription coactivator function in vitro. In
vitro transcription assays were carried out on the naked (A) and chromatin
(B,C) templates (pT3G5). The reactions contain, as indicated, the Gal4-
CREB fusion protein phosphorylated at serine 133 by PKA (P-Gal-CREB),
Gal4-CREB bearing a point mutation at serine 133 (Gal-CREB M1), and
rp300, either wild type (WT) or serine 89 point mutant (S89A) with or
without phosphorylation by PKCy. A major late core promoter (MLP)
template (pMLD53) was included as a control in all reactions.
L.W. Yuan et al. / Biochimica et Biophysica Acta 1592 (2002) 205–211 209
scription was activated vigorously on the naked template in
the presence of P-Gal-CREB and regardless of the addition
of the rp300 protein and the PKCy treatment (Fig. 4A). In
contrast, transcription on the chromatin template was re-
pressed severely in the absence of the additional rp300, and
the transcription could be derepressed markedly by the ad-
dition of either wild type rp300 or S89A mutant in the re-
action (Fig. 4C). An initial titration for p300 in transcription
on chromatin indicated that acetyl CoA enhanced p300-
participated and chromatin-dependent transcription (Fig.
4B), which was consistent with previous observation
[21,30]. When the additional wild type rp300, but not when
the S89A mutant, was phosphorylated by PKCy, the tran-
scription derepression was reduced markedly (Fig. 4C).
These observations indicated that the phosphorylation at
serine 89 caused the deregulation of transcription. The inhi-
bition of the transcription derepression on chromatin by the
phosphorylation is consistent with the repression of the
acetylation targeted by p300 after the same phosphorylation
event (Fig. 2B). Our observations suggest that the dereg-
ulation of p300-participated transcription is associated with
the inhibition of the HAT activity.
3.6. PKCd mediates coactivator repression in cells
To examine whether this PKCy-mediated transcription
regulation event also occurs in vivo, a reporter system driven
by the CRE enhancer (p(-71)SRIF-CAT) was transfected into
HeLa cells along with the expression vectors for CREB and
PKA catalytic subunit. The empty control vector or the ex-
pression vector for wild type p300 or S89A point mutant was
cotransfected. HeLa cells used in these experiments were
either wild type or the cells stably expressing PKCy CA or
DN mutant. The PKA-induced transactivation from the CRE
enhancer was repressed by PKCy CA mutant but enhanced
by PKCy DN mutant (Fig. 5). PKCy CA mutant enhanced
the phosphorylation of p300 at serine 89 and resulted in
inhibition of its HAT activity, while PKCy DN mutant
inhibited the phosphorylation (Fig. 3C). These observations
suggest that the effect on the transactivation of the reporter
gene by the PKCy mutants was associated with the phos-
phorylation-dependent alternations of p300 HAT activity.
When the p300 point mutant was cotransfected, the reporter
CAT activity was not affected significantly by the expression
of either PKCy mutant (Fig. 5), indicating that this PKCy-
mediated transcription inhibition event in vivo was also
specific to the phosphorylation of p300 at serine 89.
4. Discussion
In summary of our current study, PKCy is responsible for
the phosphorylation of p300 at serine 89 and subsequent
repression of the transcription coactivator function. Mechan-
ically, this PKCy-mediated repression of p300 function
results from direct inhibition of p300 intrinsic HAT activity
by the serine 89 phosphorylation. This study represents the
first detailed analysis of the mechanism involved in the
regulation of a transcription pathway through phosphoryla-
tion of a coactivator.
Previous reports have suggested that the amino terminus
of CBP/p300 is not required for p300 HAT activity and is
dispensable, at least with some activators, for p300 coac-
tivator activity [31,32]. In these two studies, they used the N-
terminal deletion mutants of CBP/p300. In contrast, in our
studies using the p300 wild type and point mutant from
serine 89 to alanine (S89A), we observed reduced levels of
the p300 HAT and coactivator activities upon the serine 89
phosphorylation. Phosphorylation at serine 89 may induce a
conformational change of p300 that hinders its HAT and
transcriptional function. The S89A point mutant prevents
p300 from being phosphorylated and the subsequent inhib-
itory conformational change, and may still conserve the
normal p300 function. As a result, under the normal phos-
phorylation condition, the S89A point mutant is more active
than wild type p300 in acetylation and transcriptional coac-
tivation. On the other hand, the N-terminal deletion mutants
may cause a different conformational change of p300, but
which may not alter the HAT activity and the coactivator
function. Detailed structural studies will be able to better
resolve this question in the future.
The phosphorylation of p300 at serine 89 has been de-
tected in several different types of cells [13] while PKCy is
expressed ubiquitously [14,33], suggesting that this phos-
phorylation-dependent regulation of the transcription path-
way may not be tissue-specific. Because this phosphoryla-
tion inhibits p300 intrinsic HAT activity directly, it may also
affect p300 transcription coactivator function in different
systems [13]. These observations suggest that the PKCy-
mediated serine 89 phosphorylation may have a broader
Fig. 5. PKCy inhibits p300 transcription coactivator function in vivo. HeLa
cells with stable expression of either none (– ), PKCy CA, or PKCy DN
mutant were transfected with the CRE reporter p(-71)SRIF-CAT (1 Ag),
pRc/RSV-CREB (0.5 Ag), and pRc/RSV-PKA (0.25 Ag). The expression
vector for p300 (0.5 Ag), either wild type (WT) or the serine 89 point mutant
(S89A), was cotransfected as indicated. CATactivity was normalized against
cotransfected h-galactosidase activity. Error bars represent standard
deviation (n= 3–5).
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effect on the p300-participated transcription events. The
regulation of different transcription pathways by the PKCy
may not only go through the inhibition of p300 targeting of
nucleosomal histone acetylation, but also, possibly, through
inhibiting p300 acetylation of other transcriptional factors
[34]. In addition, we should emphasize that the present
studies do not exclude the possible roles of other isoforms
of PKC in modulating the function of p300 in various cell
types and at certain stages during the cell cycle.
Several important biological functions specific to PKCy
isoform have been reported, such as regulation of G1 cyclin
expression [35], potential growth/tumor suppressor [36], and
promotion of differentiation and apoptosis [37,38]. CBP/
p300 shares these important biological functions with PKCy.
These facts support our finding that PKCy and CBP/p300
function collaboratively in the same signal transduction
pathway, which may result in the suppression of growth
and the promotion of differentiation. PKCa is a dominant
PKC isoform in HeLa cells, and was thought previously to
contribute together with PKCy to serine 89 phosphorylation
and subsequent inhibition of p300 coactivator activity [13].
In fact, we now show that effect of PKCa-mediated phos-
phorylation on the p300 HAT activity is neutralized by
phosphorylations at serine 89 and the other putative residues.
In vivo PKCa could compete with PKCy to phosphorylate
p300 and interfere with the inhibitory effect of PKCy on the
p300 HAT activity. Thus, the inhibitory effect on p300
function by serine 89 phosphorylation should be balanced
by relative levels of activated PKCa and PKCy. It is known
that PKCa and PKCy function differently during the cell
cycle [39]. Difference in dynamics of their activities at G1
phase can also be observed (Yuan, unpublished data).
Because p300 plays important regulatory roles at G1/G0
transition and during further differentiation [1], this differ-
ence in the timing of their activation may provide the basis
for the physiological role of serine 89 phosphorylation of
p300. Further study of this phosphorylation event during the
cell cycle and during the process of differentiation should
enrich our understanding of our proposed PKCy/p300-medi-
ated signal transduction pathway.
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